KCP
RMD icon

Kera Capital Partners’s ResMed RMD Stock Holding History

Kera Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$372K Buy
1,659
+818
+97% +$204K 0.05% 341
2025
Q4 		$217K Buy
841
+52
+7% +$13.3K 0.03% 506
2025
Q3 		$216K Buy
+789
New +$216K 0.03% 386

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kera Capital Partners's RMD Position: Q1 2026 in Review

Kera Capital Partners increased its ResMed (RMD) stake by 97% in Q1 2026, buying an estimated $204K and bringing the position to 1,659 shares worth $372K. The position accounts for 0.05% of the portfolio, ranked #341.

Kera Capital Partners first reported a position in RMD in Q3 2025 and has held it in 3 quarters since. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Kera Capital Partners held 1,659 shares of ResMed worth $372K as of Q1 2026.
  • Kera Capital Partners bought 818 ResMed shares in Q1 2026, an estimated $204K.
  • ResMed made up 0.05% of Kera Capital Partners's portfolio in Q1 2026, its #341 holding.
  • Kera Capital Partners first reported a position in ResMed in Q3 2025 and has held it in 3 quarters since.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Kera Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.